Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) most recently reported quarterly actual earnings per share of $-0.24 for the period ending on 2016-06-30. Prior to the company reporting, consensus estimates based on data from Zacks Research projected the company to report EPS of $-0.23. The difference between the estimate and the actual EPS was $-0.01 creating a surprise factor of -4.35%. Currently, the company has an impact score of 100. The likelihood that the stock will move on news is greater with a higher impact score. According to Beta Research, the stock has a sentiment score of 0.115. On a scale between 1 and -1, a positive score tends to portray a favorable view of company results by news outlets. The opposite is true for a negative sentiment score.

In taking a look at where the stock might be headed, analysts have a consensus price target of $14 on the shares. The most bullish brokerage firm has a $15 target, while the most bearish sees the stock headed towards $13. This is according to the 2 estimates taken into consideration by Zacks Research.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 1.67. This is according to a simplified scale where 1 represents a Strong Buy and 5 a Strong Sell recommendation. There were 2 recommendations taking into account in order to arrive at this number. Of the 2, 2 have a Strong Buy rating and 0 are rating it a Buy.

Ohr Pharmaceutical Inc (Ohr) is a biotechnology company. The Company focuses on the development of its two products, OHR/AVR118 for the treatment of cancer cachexia (multi-symptom wasting disorder), and Squalamine for the treatment of the wet form of age-related macular degeneration using an eye drop formulation. As of September 30, 2012, the Company is engaged in the clinical testing of OHR/AVR118 and the Squalamine eye drop program for the treatment of wet-AMD. On September 24, 2012, the Company announced the initiation of a multi center, randomized, placebo controlled Phase II trial to evaluate the efficacy and safety of Squalamine eye drops for the treatment of the wet form of age-related macular degeneration. In September 2012, the Company commenced a clinical study, named OHR-002.

Ohr Pharmaceuticals, Inc. - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.